WASHINGTON - Novavax Inc said on Tuesday its experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company's shares up 10 per cent.
Maryland-based Novavax said its vaccine candidate, NVX-CoV2373, produced higher levels of the antibodies in healthy volunteers after two doses than those found in recovered Covid-19 patients, raising hopes for its eventual success. Effective vaccines and treatments are considered essential to halting a pandemic that has claimed more than 695,000 lives worldwide.
The trial, which started in late May, tested the vaccine in 106 subjects aged 18 to 59 versus a placebo. The Phase I study looked at the vaccine's safety and ability to induce immune responses. Headache, fatigue, and muscle pain were among the more common side effects, and the vaccine was"well tolerated"overall, the company said.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Hermes sales plunge 42 per cent amid global coronavirus store closuresEven the Birkin bag maker isn’t immune to effects of pandemic-induced lockdowns.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Scientists worry about political influence over coronavirus vaccine projectWASHINGTON (NYTIMES) - In April, with hospitals overwhelmed and much of the United States in lockdown, the Department of Health and Human Services produced a presentation for the White House arguing that rapid development of a coronavirus vaccine was the best hope to control the pandemic.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »
Coronavirus vaccine confronts humanity with next moral testNEW YORK (BLOOMBERG) - The coronavirus pandemic has stress-tested the world.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »
Indonesia eyes production of 250 million doses a year of coronavirus vaccineJAKARTA (REUTERS) - Indonesia will have capacity to produce 250 million doses a year of a coronavirus vaccine by the end of 2020 pending trials on humans, a minister said on Tuesday (Aug 4), as the country seeks to halt a wave of infections that has shown no sign of slowing.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »
Indonesia to have capacity to produce 250 million doses of COVID-19 vaccine a yearJAKARTA: Indonesia will have capacity to produce 250 million doses a year of a coronavirus vaccine by the end of 2020 pending trials on humans, a ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Russia aims to produce 'millions' of COVID-19 vaccine doses by 2021Russia said Monday it aims to launch mass production of a coronavirus vaccine next month and turn out 'several million' doses per month by next year.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »